SPONSOR
Ascentage Pharma Group Inc.
Total Trials
5
Recruiting
5
Phases
Phase 1, Phase 1, Phase 2
Conditions studied: Platinum-resistant Recurrent Ovarian CancerAdvanced Solid TumorLiposarcomaNeuroblastomaSolid TumorAcute Myeloid Leukemia (AML)Myelodysplastic Syndromes (MDS)Relapsed/Refractory Acute Myeloid LeukaemiaMyeloid Malignancy
Ascentage Pharma Group Inc. is a clinical research sponsor with 5 registered studies on ClinicalTrials.gov, of which 5 are actively recruiting participants. Research covers conditions including Platinum-resistant Recurrent Ovarian Cancer, Advanced Solid Tumor, Liposarcoma, Neuroblastoma.
The trial portfolio spans Phase 1, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Ascentage Pharma Group Inc.
How many clinical trials has Ascentage Pharma Group Inc. sponsored?
ClinicalMetric currently tracks 5 clinical trials sponsored by Ascentage Pharma Group Inc., of which 5 are actively recruiting participants. These trials cover conditions including Platinum-resistant Recurrent Ovarian Cancer, Advanced Solid Tumor, Liposarcoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Ascentage Pharma Group Inc. research focus on?
Ascentage Pharma Group Inc. clinical trials span Platinum-resistant Recurrent Ovarian Cancer, Advanced Solid Tumor, Liposarcoma, Neuroblastoma, Solid Tumor, and additional conditions. The research pipeline includes Phase 1, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Ascentage Pharma Group Inc. clinical trial?
To participate in a Ascentage Pharma Group Inc. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Ascentage Pharma Group Inc. trials with current recruitment status updated daily.
Clinical Trials by Ascentage Pharma Group Inc.
NCT06687070 Phase 1
Recruiting
APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Platinum-resistant Recurrent Ovarian Cancer
NCT04785196 Phase 1, Phase 2
Recruiting
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Liposarcoma
NCT05701306 Phase 1, Phase 2
Recruiting
APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
Neuroblastoma
NCT04275518 Phase 1
Recruiting
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
Acute Myeloid Leukemia (AML)
NCT04501120 Phase 1, Phase 2
Recruiting
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Relapsed/Refractory Acute Myeloid Leukaemia
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology